A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial R... Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval ... Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (ne...STOCK Quote
NASDAQ: AERI
$17.50USD
Feb 28, 4:00 PM ET
VOLUME
1,493,538
DAY LOW/HIGH
$16.27/$17.56
52 - WEEK LOW/HIGH
$16.97/$50.10
